Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Med. clín (Ed. impr.) ; 159(4): 164-170, agosto 2022. tab, graf
Article in Spanish | IBECS | ID: ibc-206656

ABSTRACT

Antecedentes:El antígeno carbohidrato 125 (CA125) ha emergido como un nuevo biomarcador en insuficiencia cardiaca. El objetivo del estudio es determinar si los niveles séricos de CA125 predicen la mortalidad y reingresos totales a un año en pacientes mayores de 70 años e insuficiencia cardiaca aguda (ICA) con fracción de eyección preservada (FEP).Métodos:Estudio observacional prospectivo multicéntrico, que incluyó a 359 pacientes (edad media 81,5 años). La variable de valoración principal fue la mortalidad total por todas las causas y lo reingresos totales por ICA a un año. El análisis de regresión binomial negativa se utilizó para evaluar la asociación entre los valores de CA125 y el pronóstico.Resultados:Al año de seguimiento, se registraron 87 muertes (24,2%). Los pacientes del cuartil inferior de CA125 presentaron una tasa bruta de mortalidad menor (14,4%, 26,7, 26,7 y 29,2; p=0,090). Tras un análisis multivariado, el valor de CA125 se asoció de forma casi lineal y positiva a un mayor riesgo de mortalidad (p=0,009). Dicha asociación fue también positiva pero estadísticamente límite en el caso de los reingresos totales por ICA (p=0,089).Conclusiones:En población mayor de 70 años hospitalizada por ICA con FEP, los niveles elevados de CA125 se asocian a un aumento del riesgo de muerte a un año de seguimiento. La asociación con los reingresos fue más incierta. Los niveles bajos de CA125 identifica un subgrupo de pacientes de bajo riesgo. (AU)


Background:Carbohydrate antigen 125 (CA125) has emerged as a new biomarker in heart failure. The objective of the study is to determine whether serum CA125 levels predict total mortality and readmissions at one year in patients >70 years old with acute heart failure (AHF) and preserved ejection fraction (PEF).Methods:Multicenter prospective observational study, which included 359 patients (mean age 81.5 years). The primary endpoint was total all-cause mortality and total readmissions for AHF at 1 year. A negative binomial regression technique was used to evaluate the association between CA125 and both endpoints.Results:At one year of follow-up, 87 deaths (24.2%) were registered. The patients in the lower quartile of CA125 had a lower crude mortality rate (14.4%, 26.7, 26.7, 29.2; p=0.09). After multivariate analysis, the CA125 value was positively associated with a higher risk (p=0.009). Such association was also positive but borderline significant for the risk of readmissions (p=0.089).Conclusions:In a population older than 70 years hospitalized for AHF with PEF, elevated levels of CA125 are associated with an increased risk of death at one year of follow-up. The association with readmission for AHF was more uncertain. Low levels of CA125 identifies a subgroup at low-risk. (AU)


Subject(s)
Humans , CA-125 Antigen , Carbohydrates , Heart Failure/complications , Prognosis , Stroke Volume
2.
Med Clin (Barc) ; 159(4): 164-170, 2022 08 26.
Article in English, Spanish | MEDLINE | ID: mdl-34895749

ABSTRACT

BACKGROUND: Carbohydrate antigen 125 (CA125) has emerged as a new biomarker in heart failure. The objective of the study is to determine whether serum CA125 levels predict total mortality and readmissions at one year in patients >70 years old with acute heart failure (AHF) and preserved ejection fraction (PEF). METHODS: Multicenter prospective observational study, which included 359 patients (mean age 81.5 years). The primary endpoint was total all-cause mortality and total readmissions for AHF at 1 year. A negative binomial regression technique was used to evaluate the association between CA125 and both endpoints. RESULTS: At one year of follow-up, 87 deaths (24.2%) were registered. The patients in the lower quartile of CA125 had a lower crude mortality rate (14.4%, 26.7, 26.7, 29.2; p=0.09). After multivariate analysis, the CA125 value was positively associated with a higher risk (p=0.009). Such association was also positive but borderline significant for the risk of readmissions (p=0.089). CONCLUSIONS: In a population older than 70 years hospitalized for AHF with PEF, elevated levels of CA125 are associated with an increased risk of death at one year of follow-up. The association with readmission for AHF was more uncertain. Low levels of CA125 identifies a subgroup at low-risk.


Subject(s)
Heart Failure , Aged , Aged, 80 and over , CA-125 Antigen , Carbohydrates , Heart Failure/complications , Humans , Prognosis , Stroke Volume
3.
Cardiol J ; 20(5): 506-12, 2013.
Article in English | MEDLINE | ID: mdl-24469874

ABSTRACT

BACKGROUND: Our aim was to determine if hyponatremia, defined as serum sodium level < 135 mmol/L, is a predictor of worse outcome in a cohort of real-world patients with heartfailure (HF). METHODS: We used data of the National registry of HF (RICA) from Spain, an ongoing multicenter, prospective cohort study. The patients were assigned to two groups regarding sodium levels. Primary end-point was first all-cause readmission, or death by any cause. Secondary end-points were the number of days hospitalized, and the presence of complications. RESULTS: We identified 973 patients, 147 (15.11%) with hyponatremia. The median age of patients enrolled was 77.25 ± 8.79 years-old, the global comorbidity measured by Charlson comorbidity index (CCI) was upper 3 points and preserved ejection fraction was present in67.1% of them. Clinical complications during admission were significantly higher in the patients with hyponatremia (35.41%, p < 0.001) and this remained as significant predictor after logistic regression adjustment (OR 1.08, p < 0.01). Also mortality and readmissions were more frequent in patients with hyponatremia (20.69% and 22.41%, respectively) but after Cox regression adjustment hyponatremia in our cohort was not associated with increase in 90-day all-cause mortality and readmissions, and only CCI remained significant for primaryend-point (HR 1.08, p < 0.001). CONCLUSIONS: Hyponatremia is an independent predictor of complications during hospitalization in our real-world cohort, but was not associated with 90 days mortality or readmissions. Global comorbidity, however, played an important role, and could influence the mortality and readmissions of our patients.


Subject(s)
Heart Failure/complications , Hyponatremia/complications , Patient Admission , Acute Disease , Aged , Aged, 80 and over , Biomarkers/blood , Chi-Square Distribution , Comorbidity , Female , Heart Failure/diagnosis , Heart Failure/mortality , Heart Failure/therapy , Humans , Hyponatremia/blood , Hyponatremia/diagnosis , Hyponatremia/mortality , Hyponatremia/therapy , Kaplan-Meier Estimate , Length of Stay , Logistic Models , Male , Multivariate Analysis , Odds Ratio , Patient Readmission , Predictive Value of Tests , Prognosis , Proportional Hazards Models , Prospective Studies , Registries , Risk Factors , Sodium/blood , Spain , Time Factors
4.
Med. clín (Ed. impr.) ; 134(10): 427-432, abr. 2010. tab
Article in Spanish | IBECS | ID: ibc-82765

ABSTRACT

Fundamento y objetivo: La relevancia clínica de la insuficiencia cardiaca (IC) y de la enfermedad pulmonar obstructiva crónica (EPOC) en un mismo enfermo no está bien establecida. El objetivo de este trabajo fue estudiar la prevalencia de EPOC en pacientes ingresados por IC, definir su perfil clínico y la relación con el tratamiento con bloqueadores beta. Pacientes y método: Análisis de una cohorte prospectiva de pacientes ingresados en 15 servicios de Medicina Interna desde octubre de 2005 hasta marzo de 2006. El diagnóstico de EPOC se estableció por criterios clínicos o espirometría. Se recogieron datos sobre el tratamiento neurohormonal antes, durante y tras el ingreso hospitalario. Se utilizó la prueba de ji al cuadrado y la t de Student. Con las variables significativas se construyó un modelo de regresión logística. En todos los casos se consideró una significación bilateral para p<0,05. Resultados: Se incluyó a 391 pacientes, con una prevalencia de EPOC del 25,1%. En dos tercios de los pacientes se estableció el diagnóstico solo por criterios clínicos. El 23,5% de los enfermos tenía un estadio moderado o grave de EPOC. En el analisis bivariante se relacionó la presencia de EPOC con el sexo masculino (p<0,05), mayor índice de Charlson y mayor sobrepeso (p=0,04 ambos). En el tratamiento con bloqueadores beta adrenérgicos, solo la fracción de eyección del ventrículo izquierdo (p=0,03) y el tratamiento previo (p<0,001) tuvieron significación estadística en el modelo de regresión logística. La prescripción de betabloqueadores en el alta fue del 27,6%. Conclusiones: La prevalencia de EPOC es elevada en IC, y el perfil es el de un hombre de edad avanzada, con elevada comorbilidad y sobrepeso. El tratamiento con betabloqueadores se condiciona por el deterioro de la función ventricular, sin relación con la EPOC


Background and objective: The clinical relevance of Heart failure (HF) and chronic obstructive pulmonary disease (COPD) in the same patient is not well established. We decided to study the prevalence of COPD in patients admitted due to HF, to define their clinical profile and the relationship with adrenergic beta-blockers (BB) treatment. Patients and method: Prospective cohort of inpatients with HF admitted in 15 Internal Medicine Services from October 2005 to March 2006. Diagnosis of COPD was established according to clinical criteria or spirometry. Data about neurohormonal treatment (before, during the admission, and at discharge) were collected. Statistical analyses were performed using Ji square test and T Student test. A logistic regression model was designed with data. P<0.05 being considered statistically significant. Rokesults: About 391 patients were included . CPOD was present in 25.1% of patients. In two thirds of patients, the COPD diagnosis was established by clinical criteria. Regarding GOLD, 23.5% of patients had moderate or severe COPD severity. Bivariate analysis showed that male (<0.05), poor Charlson's Index and overweight (p=0.04 both) had all relationship with COPD. The regression model indicated that only left ventricular ejection fraction (LVEF) and BB treatment before admission had statistical significance (p=0.03 and p<0.001 respectively). At discharge, 27,6% of patients received BB. Conclusions: COPD in HF patients is common and most frequent patients are aged men high comorbidity and overweight. BB treatment is conditioned by LVEF, without relationship with COPD severity (AU)


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Aged, 80 and over , Pulmonary Disease, Chronic Obstructive/complications , Heart Failure/complications , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/drug therapy , Pulmonary Disease, Chronic Obstructive/epidemiology , Heart Failure/diagnosis , Heart Failure/drug therapy , Heart Failure/epidemiology , Comorbidity , Prospective Studies , Stroke Volume , Hypertension/epidemiology , Cohort Studies , Diabetes Mellitus/epidemiology
5.
Med Clin (Barc) ; 134(10): 427-32, 2010 Apr 10.
Article in Spanish | MEDLINE | ID: mdl-20149399

ABSTRACT

BACKGROUND AND OBJECTIVE: The clinical relevance of Heart failure (HF) and chronic obstructive pulmonary disease (COPD) in the same patient is not well established. We decided to study the prevalence of COPD in patients admitted due to HF, to define their clinical profile and the relationship with adrenergic beta-blockers (BB) treatment. PATIENTS AND METHOD: Prospective cohort of inpatients with HF admitted in 15 Internal Medicine Services from October 2005 to March 2006. Diagnosis of COPD was established according to clinical criteria or spirometry. Data about neurohormonal treatment (before, during the admission, and at discharge) were collected. Statistical analyses were performed using Ji square test and T Student test. A logistic regression model was designed with data. P<0.05 being considered statistically significant. RESULTS: About 391 patients were included . CPOD was present in 25.1% of patients. In two thirds of patients, the COPD diagnosis was established by clinical criteria. Regarding GOLD, 23.5% of patients had moderate or severe COPD severity. Bivariate analysis showed that male (<0.05), poor Charlson's Index and overweight (p=0.04 both) had all relationship with COPD. The regression model indicated that only left ventricular ejection fraction (LVEF) and BB treatment before admission had statistical significance (p=0.03 and p<0.001 respectively). At discharge, 27,6% of patients received BB. CONCLUSIONS: COPD in HF patients is common and most frequent patients are aged men high comorbidity and overweight. BB treatment is conditioned by LVEF, without relationship with COPD severity.


Subject(s)
Heart Failure/complications , Pulmonary Disease, Chronic Obstructive/complications , Adrenergic beta-Antagonists , Aged , Aged, 80 and over , Chi-Square Distribution , Chronic Disease , Cohort Studies , Comorbidity , Cross-Sectional Studies , Data Interpretation, Statistical , Diabetes Mellitus/epidemiology , Female , Heart Diseases/epidemiology , Heart Failure/diagnosis , Heart Failure/drug therapy , Heart Failure/epidemiology , Heart Failure/physiopathology , Humans , Hypertension/epidemiology , Inpatients , Logistic Models , Male , Middle Aged , Overweight , Prevalence , Prospective Studies , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/drug therapy , Pulmonary Disease, Chronic Obstructive/epidemiology , Pulmonary Disease, Chronic Obstructive/physiopathology , Risk Factors
7.
J Thromb Thrombolysis ; 28(4): 436-43, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19225864

ABSTRACT

OBJECTIVE: To analyse incidence of hemorrhagic and thrombotic events in a series of ambulatory patients receiving acenocoumarol in a rural area of Spain (1997-2007). RESULTS: Out of 1,544 patients, 1,086 are receiving acenocoumarol at present (2% of our region's population). The total follow-up was 5,462 patients-years. Median age was 74 years. INR therapeutic range was 2.0-3.0 in 82.5%. Atrial fibrillation (AF) was the most frequent indication (73%). Incidence of hemorrhagic and thrombotic events was 2.27 and 0.2/100 patients-year, respectively. Gastrointestinal tract was the most frequent site of bleeding. In multivariate analysis, patients with AF and prosthetic heart valves (PHV) had increased risk of bleeding (OR 2.1 and 4.8, respectively). Age and therapeutic ranges of INR were not associated with increased risk of bleeding. CONCLUSIONS: 2% of our population is receiving acenocoumarol. Incidence of hemorrhagic and thrombotic events was low. Patients with AF and PHV had increased risk of bleeding.


Subject(s)
Acenocoumarol/therapeutic use , Ambulatory Care/trends , Acenocoumarol/adverse effects , Adolescent , Adult , Aged , Aged, 80 and over , Cohort Studies , Female , Follow-Up Studies , Hemorrhage/chemically induced , Hemorrhage/epidemiology , Humans , International Normalized Ratio/trends , Male , Middle Aged , Outpatient Clinics, Hospital/trends , Prospective Studies , Risk Factors , Spain/epidemiology , Thrombosis/chemically induced , Thrombosis/epidemiology , Treatment Outcome , Young Adult
8.
Arch Bronconeumol ; 44(3): 173-4, 2008 Mar.
Article in Spanish | MEDLINE | ID: mdl-18361890

ABSTRACT

Organizing pneumonia is a well-differentiated clinical and histologic entity whose onset is usually subacute with respiratory symptoms and pulmonary infiltrates. Its origin may be unknown (cryptogenic) or it may be associated with various medical conditions, infectious diseases, or drugs. Diagnosis is confirmed by the presence of foci of organizing pneumonia in lung biopsy specimens. Our patient was a 49-year-old man infected with the hepatitis C virus who was receiving pegylated interferon alfa-2b. He presented with dry cough, fever, dyspnea, and ground glass pulmonary infiltrates. After an open lung biopsy, he was diagnosed with organizing pneumonia. When pegylated interferon was discontinued and corticosteroids started, the symptoms and pulmonary infiltrates disappeared. To our knowledge, this is the second report of organizing pneumonia related to pegylated interferon alfa-2b.


Subject(s)
Antiviral Agents/adverse effects , Cryptogenic Organizing Pneumonia/chemically induced , Interferon-alpha/adverse effects , Humans , Interferon alpha-2 , Male , Middle Aged , Recombinant Proteins
9.
Arch. bronconeumol. (Ed. impr.) ; 44(3): 173-174, mar. 2008. ilus
Article in Es | IBECS | ID: ibc-64053

ABSTRACT

La neumonía organizada es una entidad clínico-histológica bien diferenciada, que suele presentarse de forma subaguda con síntomas respiratorios e infiltrados pulmonares. Puede ser de causa desconocida (criptogenética) o estar asociada a distintas enfermedades, infecciones o fármacos. El diagnóstico de seguridad requiere la demostración de focos de neumonía organizada en muestras de biopsia pulmonar. Presentamos el caso de un paciente de 49 años con infección por el virus de la hepatitis C en tratamiento con peginterferón a-2b que desarrolló un cuadro de tos seca, fiebre, disnea e infiltrados pulmonares en vidrio deslustrado, y a quien se diagnosticó por biopsia pulmonar abierta de neumonía organizada. Con la retirada del peginterferón y tratamiento con corticoides desaparecieron los síntomas y los infiltrados pulmonares. En nuestro conocimiento, éste es el segundo caso comunicado de neumonía organizada en relación con peginterferón afa-2b (AU)


Organizing pneumonia is a well-differentiated clinical and histologic entity whose onset is usually subacute with respiratory symptoms and pulmonary infiltrates. Its origin may be unknown (cryptogenic) or it may be associated with various medical conditions, infectious diseases, or drugs. Diagnosis is confirmed by the presence of foci of organizing pneumonia in lung biopsy specimens. Our patient was a 49-year-old man infected with the hepatitis C virus who was receiving pegylated interferon alfa-2b. He presented with dry cough, fever, dyspnea, and ground glass pulmonary infiltrates. After an open lung biopsy, he was diagnosed with organizing pneumonia. When pegylated interferon was discontinued and corticosteroids started, the symptoms and pulmonary infiltrates disappeared. To our knowledge, this is the second report of organizing pneumonia related to pegylated interferon alfa-2b (AU)


Subject(s)
Humans , Male , Middle Aged , Interferon alpha-2/adverse effects , Antiviral Agents/adverse effects , Pneumonia/chemically induced , Interferon alpha-2/therapeutic use , Antiviral Agents/therapeutic use , Hepatitis C/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...